Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial

被引：0
|
作者：
Bajaj, Jasmohan [1 ]
Yeramian, Patrick [2 ]
Gavis, Edith [1 ]
Fagan, Andrew [1 ]
Fischer, James [3 ]
Garcia-Tsao, Guadalupe [4 ]
Angeli, Paolo [5 ]
Smith, Denise [2 ]
Adams, Jonathan [2 ]
Markham, Penelope [2 ]
机构：
[1] Hunter Holmes McGuire VA Ctr, Richmond, VA USA
[2] BioVie Inc, Los Angeles, CA USA
[3] Univ Illinois, Coll Pharm, Chicago, IL USA
[4] Yale Sch Med, New Haven, CT USA
[5] Univ Padua, Med, Padua, Italy
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT139
引用
收藏
页码：S718 / S719
页数：2
相关论文
共 50 条
  • [21] A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer
    Jaafar Bennouna
    Marion Deslandres
    Helene Senellart
    Cecile de Labareyre
    Rodrigo Ruiz-Soto
    Claire Wixon
    Jeff Botbyl
    A. Benjamin Suttle
    Jean-Pierre Delord
    Investigational New Drugs, 2015, 33 : 138 - 147
  • [22] A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer
    Bennouna, Jaafar
    Deslandres, Marion
    Senellart, Helene
    de Labareyre, Cecile
    Ruiz-Soto, Rodrigo
    Wixon, Claire
    Botbyl, Jeff
    Suttle, A. Benjamin
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 138 - 147
  • [23] Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors
    L. Rhoda Molife
    Sarah M. Rudman
    Salma Alam
    Daniel S.-W. Tan
    Hartmut Kristeleit
    Gary Middleton
    David Propper
    Liz Bent
    Peter Stopfer
    Martina Uttenreuther-Fischer
    Gudrun Wallenstein
    Johann de Bono
    James Spicer
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1213 - 1222
  • [24] Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors
    Molife, L. Rhoda
    Rudman, Sarah M.
    Alam, Salma
    Tan, Daniel S. -W.
    Kristeleit, Hartmut
    Middleton, Gary
    Propper, David
    Bent, Liz
    Stopfer, Peter
    Uttenreuther-Fischer, Martina
    Wallenstein, Gudrun
    de Bono, Johann
    Spicer, James
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (06) : 1213 - 1222
  • [25] Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study
    Tom, Wynnis L.
    Van Syoc, Merrie
    Chanda, Sanjay
    Zane, Lee T.
    PEDIATRIC DERMATOLOGY, 2016, 33 (02) : 150 - 159
  • [26] A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lympboprolifierative Malignancies
    Horwitz, Steven M.
    Vose, Julie M.
    Advani, Ranjana
    Sankhala, Kamalesh
    Padmanabhan, Swaminathan
    Hamlin, Paul A., Jr.
    Chen, Andy
    Wilroy, Shannon
    Zain, Jasmine M.
    Wright, Danielle
    Weissbrot, Hanna
    Hohenstein, Maribeth
    Cagnoni, Pablo J.
    Saunders, Michael E.
    O'Connor, Owen A.
    BLOOD, 2008, 112 (11) : 557 - 557
  • [27] The Shortened Infusion Time of Intravenous Ibuprofen, Part 2: A Multicenter, Open-label, Surgical Surveillance Trial to Evaluate Safety
    Gan, Tong J.
    Candiotti, Keith
    Turan, Alparslan
    Buvanendran, Asokumar
    Philip, Beverly K.
    Viscusi, Eugene R.
    Soghomonyan, Suren
    Bergese, Sergio D.
    CLINICAL THERAPEUTICS, 2015, 37 (02) : 368 - 375
  • [28] Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
    Fowler, Nathan H.
    Davis, R. Eric
    Rawal, Seema
    Nastoupil, Loretta
    Hagemeister, Fredrick B.
    McLaughlin, Peter
    Kwak, Larry W.
    Romaguera, Jorge E.
    Fanale, Michelle A.
    Fayad, Luis E.
    Westin, Jason R.
    Shah, Jatin
    Orlowski, Robert Z.
    Wang, Michael
    Turturro, Francesco
    Oki, Yasuhiro
    Claret, Linda C.
    Feng, Lei
    Baladandayuthapani, Veerabhadran
    Muzzafar, Tariq
    Tsai, Kenneth Y.
    Samaniego, Felipe
    Neelapu, Sattva S.
    LANCET ONCOLOGY, 2014, 15 (12): : 1311 - 1318
  • [29] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients
    Chu, Q
    Cianfrocca, ME
    Murray, N
    Oslund, M
    Nelson, LM
    Rowinsky, E
    Schwartz, G
    Goldstein, LJ
    Loftiss, JI
    Paul, E
    Koch, KM
    Pandite, L
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S235 - S235
  • [30] Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study
    Fleischmann, Roy
    Winkle, Peter
    Hall, Jesse
    Valdez, Shakti
    Liu, Sha
    Yan, Xiaohong
    Hicks, Liz
    Hernandez-Illas, Martha
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345